Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) Tax Provisions (2021 - 2026)

Atea Pharmaceuticals' Tax Provisions history spans 6 years, with the latest figure at $50000.0 for Q1 2026.

  • Quarterly Tax Provisions fell 75.37% to $50000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$6.3 million through Mar 2026, down 804.01% year-over-year, with the annual reading at -$6.2 million for FY2025, 766.16% down from the prior year.
  • Tax Provisions came in at $50000.0 for Q1 2026, up from -$6.8 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $349000.0 in Q4 2023 to a low of -$6.8 million in Q4 2025.
  • The 5-year median for Tax Provisions is $205000.0 (2025), against an average of -$484937.5.
  • Year-over-year, Tax Provisions surged 183.74% in 2023 and then plummeted 3108.0% in 2025.
  • Atea Pharmaceuticals' Tax Provisions stood at $123000.0 in 2022, then soared by 183.74% to $349000.0 in 2023, then tumbled by 35.53% to $225000.0 in 2024, then tumbled by 3108.0% to -$6.8 million in 2025, then skyrocketed by 100.74% to $50000.0 in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Tax Provisions are $50000.0 (Q1 2026), -$6.8 million (Q4 2025), and $196000.0 (Q3 2025).